Pancreatic Cancer Research

ResearcherWayne State UniversityActive in the last 2 years

Mandana Kamgar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9364-2712; OpenAlex author ID A5013768762. Sources: ClinicalTrials.gov.

Their work

Papers
27 (first author 7, last author 2)
Trials
4 (principal investigator on 4)
Grants
0
Labs led
1
Collaborators
65
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 4 papers · 2022: 1 paper, 1 trial · 2023: 5 papers, 2 trials · 2024: 5 papers, 1 trial · 2025: 2 papers · 2026: 5 papers

Papers 27

  1. AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.0291↗
  2. MEK inhibitor-based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations. Last author DOI 10.1093/oncolo/oyag040↗
  3. Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenoca… Co-author DOI 10.1158/0008-5472.can-25-0018↗
  4. Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-1181↗
  5. The Evolution of Oligometastatic Pancreatic Ductal Adenocarcinoma: From Anatomic Description to Biologically Informed Patient Selection. Co-author DOI 10.3390/cancers18203376↗
  6. Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes. Co-author DOI 10.1016/j.prro.2024.07.001↗
  7. Bridging the Gap: Molecular Profiling to Guide Treatment Selection in Metastatic Pancreatic Cancer. Co-author DOI 10.1200/jco-25-01298↗
  8. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy. Co-author DOI 10.1002/cam4.6582↗
  9. A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Co-author DOI 10.1016/j.redox.2024.103375↗
  10. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.028↗
  11. Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review. First author DOI 10.1159/000536552↗
  12. Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series. Last author DOI 10.1177/17588359241253113↗
  13. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity. Co-author DOI 10.1002/jso.27265↗
  14. Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. First author DOI 10.1016/j.adro.2022.101122↗
  15. Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005884↗
  16. A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Res… Co-author DOI 10.1245/s10434-022-12742-3↗
  17. CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. First author DOI 10.1245/s10434-022-13055-1↗
  18. Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. First author DOI 10.3390/cancers14112588↗
  19. Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. First author DOI 10.1007/s10555-021-09993-z↗
  20. Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.soc.2021.06.004↗
  21. Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2020.06.038↗
  22. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09149-3↗
  23. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cance… Co-author DOI 10.1016/j.surg.2020.04.031↗
  24. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-1728↗
  25. Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth. Co-author DOI 10.3390/cancers12030750↗
  26. Goals of Treatment Sequencing for Localized Pancreatic Cancer. First author DOI 10.1245/s10434-019-07738-5↗
  27. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. First author DOI 10.1080/14737140.2018.1417844↗

Trials 4

  1. Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence Principal investigator NCT06228599↗
  2. A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy Principal investigator NCT05630989↗
  3. Determining Individualized Cancer Therapy in Pancreatic Cancer Principal investigator NCT05914987↗
  4. CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma Principal investigator NCT05325281↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. William Adrian Hall · 16 shared papers, 2020–2026 · strength 2.80
  2. Douglas B. Evans · 16 shared papers, 2019–2026 · strength 2.77
  3. Susan Tsai · 16 shared papers, 2019–2026 · strength 2.58
  4. Mohammed Aldakkak · 11 shared papers, 2020–2026 · strength 1.98
  5. Kathleen K. Christians · 12 shared papers, 2020–2026 · strength 1.96
  6. Razelle Kurzrock · 5 shared papers, 1 shared trial, 2024–2026 · strength 1.55
  7. Callisia Nathelee Clarke · 9 shared papers, 2020–2026 · strength 1.48
  8. Bradley A. Erickson · 10 shared papers, 2020–2024 · strength 1.46
  9. Ben George · 10 shared papers, 2020–2024 · strength 1.46
  10. Thomas B. McFall · 6 shared papers, 2024–2026 · strength 1.37
  11. Sam Z. Thalji · 6 shared papers, 2023–2026 · strength 1.18
  12. Beth E. Erickson · 4 shared papers, 2024–2026 · strength 0.81
  13. Yongwoo David Seo · 3 shared papers, 2026 · strength 0.77
  14. Douglas B. Evans · 1 shared paper, 1 shared trial, 2024–2026 · strength 0.77
  15. Kulwinder S. Dua · 5 shared papers, 2020–2025 · strength 0.75
  16. Nikki K. Lytle · 3 shared papers, 2026 · strength 0.64
  17. Sakti Chakrabarti · 3 shared papers, 2021–2024 · strength 0.63
  18. Asfar Sohail Azmi · 5 shared papers, 2018–2023 · strength 0.59
  19. Ben George · 3 shared papers, 2024–2026 · strength 0.59
  20. Andrew H. Ko · 1 shared paper, 2025 · strength 0.54
  21. Philip A. Philip · 4 shared papers, 2018–2023 · strength 0.47
  22. Juhi Mody · 1 shared paper, 2024 · strength 0.46
  23. Daniel Dorbin · 2 shared papers, 2026 · strength 0.41
  24. G. Aaron Hobbs · 2 shared papers, 2026 · strength 0.41
  25. Naveen M. Kulkarni · 3 shared papers, 2020–2023 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.